R&D Experimental Services: COVID-19 Research

In response to the COVID-19 pandemic, R&D service companies have created research models and tools adapted to SARS-CoV-2: in vitro assays on Vero E6, Caco-2, Calu-3 models or ex vivo on epithelial airway explants (HAE), in vivo tests on hACE2 humanized mice or on golden hamster, with the use of original, alpha, delta or omicron variants, for the development of COVID-19 drugs, vaccines, validation of immunological, PCR or side-flow diagnostic kits, measurement of virucidal effects of materials directly on SARS-CoV-2.

Finding the right laboratory with the set of competencies required for a COVID-19 project, however, can be difficult.

This is why Labtoo developed a tailor-made service to support Labs, Biotechs, Medtech, and Pharma companies in their SARS-CoV-2 research programs.

Labtoo can look for any type of SARS-CoV-2 experimental services,  for the development of new drugs and the development of diagnostics assays. We work with a large international network of laboratories and service companies to provide the largest options for your project.

What is included in our services?

Our team will handle your R&D service management from the beginning to the end

Perform a feasibility study by looking for existing expertise available within the network of partners

Set up a study protocole, financial quotation and preparing contracts with lab partners

Implement the study plan into a schedule, collect all needed materials and reagents and execute the service

Do you need more information about our experimental services?

How are the service providers selected?

At Labtoo, we have built a network of 500 service providers from academia, hospitals and private companies. 
We are very closely with our customers to understand exactly what is needed: is it a strong expertise on a scientific domain, or a technological requirement, or a little bit of both.
We have developed a unique method to qualify and select the best partner for each project
During the feasibility study that we carry out with our customers, we will ask a series of questions that will allow us to move forward in full confidence.

Selecting the right structure type

When looking for a CRO, there are several choices: generalist or specialized CRO, small or large structure, well-known or not... While a large CRO recognized internationally instills confidence and allows more flexibility, small and medium-sized CROs in France or Europe offer a tailor-made and highly specialized service (cancerology, neurology, cardiology, etc.) that may be more relevant to your project. Moreover, size and quality are not always correlated. 

Defining a budget 

Even if a low price is an important criterion, it should not be the major one. If a services provider seems more relevant and more competent, although more expensive, it may be worthwhile to concede to a more substantial investment, which may protect further from additional costs (due to deadlines issues, or even a change of services provider during the study).

Rely on trust... or on a previous experience!

Delays in the preclinical phases can be extremely damaging to small structures and may even jeopardize their survival. Therefore, all R&D providers must be considered trustworthy partners. When presenting the project, he must be critical of the provided elements and challenge the protocol that you are submitting to him. Good advice will save time and thus money, and a realistic time frame and a presentation of the risks involved are must-haves. And of course, getting insights from a preliminary experience is likely to help to choose.

Experience, certifications, and regulatory compliance

Depending on the stage of the project, certifications and compliance with processes might be required. It is mandatory to acquire good practices as soon as possible in the drug development process.
favicon large un peu plus-1